false
--12-31
0001533743
0001533743
2024-01-18
2024-01-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): January
18, 2024
Commission
file number 001-39531
PROCESSA
PHARMACEUTICALS, INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware |
|
45-1539785 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S.
Employer
Identification Number) |
7380
Coca Cola Drive,
Suite
106,
Hanover,
Maryland
21076 |
(Address
of Principal Executive Offices, Including Zip Code) |
(443)
776-3133 |
(Registrant’s
Telephone Number, Including Area Code) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common
stock: Par value $.0001 |
|
PCSA |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging
growth company ☐ |
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
Item
3.03 Material Modification to Rights of Security Holders
To
the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated
herein by reference.
Item
5.03 Amendments to articles of incorporation or bylaws; change in fiscal year
On
January 18, 2024, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware
a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate
of Incorporation to effect a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding
shares of common stock, par value $0.0001 per share (the “Common Stock”), effective as of 12:01 a.m. Eastern Time on January
22, 2024. Beginning with the opening of trading on January 22, 2024, Processa’s Common Stock will trade on the Nasdaq Capital Market
on a split-adjusted basis under new CUSIP number 74275C304 and will continue to trade under the symbol “PCSA.”
As
a result of the Reverse Stock Split, every twenty (20) shares of Common Stock issued and outstanding will be converted into one (1) share
of Common Stock. We will not be issuing fractional shares in connection with the Reverse Stock Split. Stockholders who
otherwise would be entitled to receive fractional shares because they hold a number of shares not evenly divisible by the reverse stock
split ratio of the Reverse Stock Split, will be entitled, upon surrender of certificate(s) representing these shares, to a number of
shares rounded up to the nearest whole number and, accordingly, no money will be paid for a fractional share.
The
Reverse Stock Split will not reduce the number of authorized shares of Common Stock of 100,000,000 or change the par value of the Common
Stock. The Reverse Stock Split will affect all stockholders uniformly and will not affect any stockholder’s ownership percentage
of the Company’s shares of Common Stock except for the impact of fractional shares.
All
outstanding options, warrants, restricted stock units and similar securities entitling their holders to receive or purchase shares of
Common Stock will be adjusted as a result of the Reverse Stock Split, as required by the terms of each security.
The
foregoing description of the Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company
is a summary of the material terms thereof, does not purport to be complete and is qualified in its entirety by reference to the full
text of the Certificate of Amendment, which is filed with this report as Exhibit 3.1 and is incorporated herein by reference.
On
January 18, 2024, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is filed herewith
as Exhibit 99.1 hereto.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized, on January 18, 2024.
|
PROCESSA
PHARMACEUTICALS, INC. |
|
Registrant |
|
|
|
|
By: |
/s/
George Ng |
|
|
George
Ng |
|
|
Chief
Executive Officer |
Exhibit
3.1
CERTIFICATE
OF AMENDMENT
TO
THE
FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
PROCESSA PHARMACEUTICALS, INC.
Processa
Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law
of the State of Delaware (the “DGCL”), hereby certifies as follows:
| 1. | This
Certificate of Amendment (the “Certificate of Amendment”) amends the provisions
of the Corporation’s Fourth Amended and Restated Certificate of Incorporation filed
with the Secretary of State of the State of Delaware on September 27, 2017, as amended on
October 23, 2017, August 12, 2019, December 19, 2019, June 29, 2020, January 3, 2022, and
June 29, 2023 (the “Certificate of Incorporation”). |
| 2. | The
Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242
of the DGCL setting forth a proposed amendment to the Certificate of Incorporation and declaring
said amendment to be advisable. The amendment amends the Certificate of Incorporation as
follows: |
| (a) | Section
A of the Certificate of Incorporation setting forth the powers, privileges and rights, and
the qualifications, limitations or restrictions thereof in respect of each class of capital
stock of the Corporation is hereby supplemented by addition of the following paragraphs as
new subsection 5 under “A. Common Stock”: |
5.
Reverse Stock Split. Upon this Certificate of Amendment becoming effective pursuant to the General Corporation Law of the State
of Delaware (the “Effective Time”), the shares of Common Stock issued and outstanding or held in treasury immediately prior
to the Effective Time (the “Old Common Stock”) shall be reclassified into a different number of shares of Common Stock (the
“New Common Stock”) such that each twenty shares of Old Common Stock shall, at the Effective Time, be automatically reclassified
into one share of New Common Stock. From (the “Reverse Stock Split”) and after the Effective Time, certificates representing
the Old Common Stock shall represent the number of whole shares of New Common Stock into which such Old Common Stock shall have been
reclassified pursuant to the immediately preceding sentence. No fractional shares of Common Stock shall be issued as a result of such
reclassification. Stockholders who otherwise would be entitled to receive fractional shares because they hold a number of shares not
evenly divisible by the reverse stock split ratio of the Reverse Stock Split, will be entitled, upon surrender of certificate(s) representing
these shares, to a number of shares rounded up to the nearest whole number and, accordingly, no money will be paid for a fractional share.
From
and after the Effective Time, the term “New Common Stock” as used in this Section shall mean the Common Stock as provided
in this Certificate of Incorporation, as amended and as further amended by this Certificate of Amendment. The par value of the New Common
Stock shall be $0.0001 per share.
| 3. | The
requisite stockholders of the Corporation have duly approved this Certificate of Amendment
in accordance with Section 242 of the DGCL. |
| 4. | This
Certificate of Amendment shall be effective at 12:01 a.m. Eastern Time on January 22, 2024. |
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed as of the date set forth below.
Dated:
January 18, 2024 |
PROCESSA
PHARMACEUTICALS, INC. |
|
|
|
|
By:
|
/s/
James Stanker |
|
Name: |
James Stanker |
|
Title: |
Chief Financial Officer |
Exhibit 99.1
Processa Pharmaceuticals to Effect a 1-for-20 Reverse
Stock Split
HANOVER, MD, January 18, 2024 (GLOBE NEWSWIRE)
-- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical
company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering
from cancer, announces that in conjunction with stockholder approval of the reverse stock split
on November 14, 2023, the Company’s Board of Directors, on January 8, 2024, determined to fix a split ratio of 1-for-20.
The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Monday, January
22, 2024. Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under
the symbol “PCSA” with the new CUSIP number 74275C304. The reverse stock split is intended for the Company to regain compliance
with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market.
At the
effective time of the reverse stock split, every twenty (20) issued and outstanding shares of the Company’s common stock will be
automatically converted into one (1) share of the Company’s common stock without any change in the par value per share. The Company
will not be issuing fractional shares in connection with the reverse stock split. Stockholders who otherwise would be entitled
to receive fractional shares, because they hold a number of shares not evenly divisible by the reverse stock split ratio of the reverse
stock split, will be entitled, upon surrender of certificate(s) representing these shares, to a number of shares rounded up to the nearest
whole number and, accordingly, no money will be paid for a fractional share.
The reverse
stock split will reduce the number of shares of the Company’s outstanding common stock from approximately 24.6 million shares
to approximately 1.2 million shares. As a result of the anticipated reverse stock split, proportionate adjustments will be made
to the number of shares of the Company’s common stock underlying the Company’s outstanding equity awards, warrants, and the
number of shares issuable under the Company’s equity incentive plans and other existing agreements, as well as the exercise price,
as applicable. The reverse stock split will have no effect on the number of authorized shares or the par value of the Company’s
common stock, and the ownership percentage of each stockholder will remain unchanged other than as a result of fractional shares.
The Company’s
transfer agent, Continental Stock Transfer & Trust, will serve as the exchange agent for the reverse stock split.
Registered
stockholders that hold shares of pre-split common stock in the Company electronically in book-entry form are not required to take any
action in order to receive post-split shares of common stock. For stockholders that hold shares of common stock in certificate form,
such stockholders will receive a transmittal letter from Continental Stock Transfer & Trust as soon as practical following the
effective date containing instructions.
Stockholders
that hold their shares of common stock either in a brokerage or in “street name”
will have their shares of common stock automatically adjusted to reflect the reverse stock split, subject to compliance with each broker’s
particular processes. Such stockholders will not be required to take any separate action in connection with the reverse stock split.
Additional
information about the reverse stock split can be found in the Company’s definitive proxy statement (the “Proxy Statement”)
filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2023, which is available free of charge at the
SEC’s website, www.sec.gov.
About Processa Pharmaceuticals,
Inc.
Processa
is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and
efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and the
Processa Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will
be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy
(NGC) drugs following an efficient path to approval. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs
resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms
of killing the cancer cells. The company’s approach to drug development is based on more than 30 years of drug development expertise
to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. The Processa team has a track
record of obtaining over 30 approvals for indications across almost every division of FDA. Using its proven Regulatory Science Approach,
the Processa Team has experience defining the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology
initiative. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose
discontinuation, more significant cancer response and a greater number of patients -- in excess of 200,000 for each NGC drug -- who will
benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine
(PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine
(PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal,
gastrointestinal, pancreatic, and other cancers).
For more
information, visit our website at www.processapharma.com.
Forward-Looking
Statements
This release
contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements
which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking
statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms
10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking
statements.
For
More Information:
Investors:
Bret Shapiro
CORE IR
ir@processapharma.com
Company
Contact:
Patrick
Lin
(925) 683-3218
plin@processapharma.com
v3.23.4
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Apr 2024 to May 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From May 2023 to May 2024